Seegene and Eidia Collaborate to Bring New Multiplex Molecular Diagnostic Tests
GAITHERSBURG, MD and SEOUL, KOREA -- (Marketwired) -- 07/01/13 --
Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplexed
molecular technologies and diagnostic tests, today announced that it
has entered into a collaboration agreement with Eidia, the in vitro
diagnostics subsidiary arm of Eisai Co., Ltd. (TSE: 4523), a world
leader in pharmaceuticals headquartered in Japan. Through this
agreement, Eidia gains access to Seegene's portfolio of TOCE(TM)
technology-based multiplexed molecular diagnostic (MoDx) tests for
the large Japanese diagnostic test market.
"Our partnership with Eidia opens a significant sales channel for our
novel diagnostic tests in Japan. We look forward to working with
Eidia to improve patient healthcare with highly sensitive and
specific multiplexed MoDx tests," said Dr. Jong-Yoon Chun, founder,
CTO and CEO of Seegene. "This deal with Eidia further supports
Seegene's leadership in multiplexed molecular technologies and
enhances Seegene's strategic market presence in Asia."
Under the terms of the agreement, Seegene will supply a wide range of
TOCE(TM) technology-based multiplexed molecular diagnostic tests, and
Eidia will exclusively market and distribute them in Japan. In
addition, Eidia will be responsible for obtaining regulatory
clearance from the Japanese Pharmaceutical and Medical Device Agency.
Enhancing Seegene's market presence in Japan is a key part of
Seegene's long-term growth strategy. Partnering with Eidia, an in
vitro diagnostic market leader in Japan, will accelerate the adoption
of innovative MoDx in that market.
Japan is the third largest diagnostics market in the $52 billion
global diagnostics industry, behind North America and Europe.
About DPO and TOCE technologies
DPO(TM) technology is a fundamental
tool for blocking extension of non-specifically primed templates
generating consistently high specificity. TOCE enables simultaneous
multiple assay testing, by separating genes (that have been amplified
with the real-time PCR technology) using the differences in their
melting temperatures. Prior to TOCE, multiple assays were difficult
because even a small variation in the amplified gene sequence changes
the melting temperature of the genes; and reduces the number of
fluorescent signals that can be tested at the same time, due to
fluorescent intervention among amplified genes. TOCE technology
overcomes these limitations. It allows testing of multiple pathogens
with one fluorescent material by ensuring that sequence variation
does not change the melting temperature of the genes.
Seegene is the world's leading developer of multiplex
molecular technologies and multiplex clinical molecular diagnostics
(M-MoDx). Seegene's core enabling technologies -- ACP(TM), DPO(TM),
READ, and TOCE(TM) -- are the foundation for M-MoDx tests that can
simultaneously detect multiple targets with high sensitivity,
specificity and reproducibility. Seegene's products detect
multi-pathogens with great reliability and throughput, ultimately
providing the most economical basis for saving time, labor and cost.
Seegene's mission is to maintain leadership in molecular diagnostics
for infectious diseases, genetics, pharmacogenetics, and oncology
using innovative proprietary technologies.
For more information please visit www.seegene.com or call
Jason Bae, Ph.D.
Base Pair Group
Press spacebar to pause and continue. Press esc to stop.